Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (113)
Cancellation by sponsor (63)
Australian Public Assessment Report (AusPAR) (44)
Prescription medicine registration (42)
Designation or determination (21)
Prescription medicine evaluation (15)
Prescription medicine decision summary (11)
Section 14, TGO91 consent (1)

Date

2024 (37)
2023 (32)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (10)
2012 (3)
2011 (6)
2010 (4)
2008 (3)
2007 (1)
2006 (8)
2004 (2)
2003 (5)
2002 (3)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Results for "[search-keyword]"

Search

Sponsor content

310 result(s) found, displaying 231 to 240

KOMBIGLYZE 2.5/850 saxagliptin (as hydrochloride)/metformin hydrochloride 2.5 mg/850 mg immediate release film-coated tablet blister Cancellaed under s30(1)

18 August 2016

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AusPAR: Naloxegol oxalate

1 June 2016

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Naloxegol oxolate
FORXIGA dapagliflozin (as propanediol monohydrate) 10 mg film-coated tablet blister pack (180147)

22 October 2012

ARTG

Australian Register of Therapeutic Goods (ARTG) information for FORXIGA dapagliflozin (as propanediol monohydrate) 10 mg film-coated tablet blister pack.
SYMBICORT RAPIHALER budesonide / formoterol fumarate dihydrate 100/3 pressurised metered dose inhaler (158899)

26 July 2012

ARTG

Australian Register of Therapeutic Goods (ARTG) information for SYMBICORT RAPIHALER budesonide / formoterol fumarate dihydrate 100/3 pressurised metered dose inhaler.
XYLOCAINE 2% With Adrenaline 1:80,000 (Ampoule) (Lignocaine + Adrenaline) Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
Xylocaine 5% Adhesive Ointment (lignocaine) Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
XYLOCAINE 1.5% lignocaine hydrochloride 375mg/25mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
MARCAIN 0.75% bupivacaine hydrochloride 75mg/10mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
MARCAIN 0.375% bupivacaine hydrochloride 37.5mg/10mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
XYLOCAINE 1.5% lignocaine hydrochloride 300mg/20mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd

Pages

First page
Previous page
…
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.